Aura Biosciences to Present Phase 2 Data on Belzupacap Sarotalocan for Choroidal Melanoma at Retina Society Annual Meeting

Aura Biosciences announced that final data from its phase 2 study on the suprachoroidal administration of belzupacap sarotalocan (bel-sar) for treating small choroidal melanoma and indeterminate lesions will be presented at the Retina Society Annual Meeting. The event will take place from September 11-15, 2024, in Lisbon, Portugal.

Presentation Details:

• Title: Final Results of a Phase 2 Trial of Suprachoroidal Administration of Belzupacap Sarotalocan (bel-sar, AU-011) for Choroidal Melanoma
• Presenter: Ivana Kim, MD, Mass Eye and Ear
• Date/Time: Thursday, September 12, 2024, from 11:04 am to 11:09 am Western European Daylight Time (6:04 am to 6:09 am Eastern Time)

The presentation will be available online following the session on September 12, 2024.

In conjunction with this presentation, Aura Biosciences will host a virtual ocular oncology investor event featuring leading experts in the field, Dr. Ivana Kim from Mass Eye and Ear and Dr. Prithvi Mruthyunjaya from Stanford University Byers Eye Institute. The event will focus on discussing the phase 2 end-of-study data and will take place on Thursday, September 12, 2024, at 8:00 am Eastern Time.

Investors and interested parties can register for the virtual event here. The event will include a live question-and-answer session following the formal discussion, allowing participants to engage directly with the presenters.